LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

LLY

1,078.02

+0.1%↑

JNJ

209.35

+0.9%↑

ABBV

231.6

+0.63%↑

UNH

330.51

-0.33%↓

AZN

92.71

-0.19%↓

Kodu・Aktsiate loetelu・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Avatud

16.66 0.12

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.46

Max

16.73

Põhinäitajad
By Trading Economics
Sissetulek	35M 9.5M
Müük	35M 94M
Aktsiakasum	0.06
Kasumimarginaal	10.158
Töötajad	619
EBITDA	35M 17M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+23.35% upside

Turustatistika
By TradingEconomics
Turukapital	17M 2.7B
Eelmine avamishind	16.54
Eelmine sulgemishind	16.66

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

8.81 / 10.18 Toetus ja vastupanu

Adaptive Biotechnologies Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. dets 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

28. dets 2025, 23:57 UTC

Tulu

'Avatar: Fire and Ash' Tops Domestic Box Office Again -- Barrons.com

28. dets 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. dets 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28. dets 2025, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

28. dets 2025, 10:30 UTC

Omandamised, ülevõtmised, äriostud

There's No Happy Ending for Movie Theaters, No Matter Who Wins Warner -- Heard on the Street -- WSJ

26. dets 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26. dets 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26. dets 2025, 19:24 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26. dets 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26. dets 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26. dets 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26. dets 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26. dets 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26. dets 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26. dets 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26. dets 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26. dets 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26. dets 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26. dets 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. dets 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26. dets 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26. dets 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26. dets 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26. dets 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25. dets 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25. dets 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25. dets 2025, 00:20 UTC

Omandamised, ülevõtmised, äriostud

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24. dets 2025, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24. dets 2025, 21:26 UTC

Omandamised, ülevõtmised, äriostud

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

Võrdlus sarnastega

Hinnamuutus

Adaptive Biotechnologies Corp Prognoos

Hinnasiht

By TipRanks

23.35% tõus

12 kuu keskmine prognoos

Keskmine 20.6 USD 23.35%

Kõrge 22 USD

Madal 20 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Adaptive Biotechnologies Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

Osta

Hoia

Müü

Põhineb 7 analüütiku instrumendi Adaptive Biotechnologies Corp aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

8.81 / 10.18Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.